REGN — REGENERON PHARMACEUTICALS, INC. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

6 verified catalyst event(s) for REGENERON PHARMACEUTICALS, INC. (ticker REGN). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-10-07 — Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months t · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-10-07 in 2mo ESTIMATED	READOUT Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥ Phase 3 · Atopic Dermatitis	REGN REGENERON PHARMACEUTICALS, I	Dupilumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-12 in 2mo ESTIMATED	READOUT A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and H Phase 3 · Paroxysmal Nocturnal Hemoglobinuria	REGN REGENERON PHARMACEUTICALS, I	Ravulizumab, Pozelimab, Cemdisiran, Ecul	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-02 in 3mo ESTIMATED	READOUT A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti- Phase 2 · Melanoma	REGN REGENERON PHARMACEUTICALS, I	cemiplimab, Fixed Dose Combination (FDC)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-13 in 3mo ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-13 in 3mo ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-03 in 4mo ESTIMATED	READOUT A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)	REGN REGENERON PHARMACEUTICALS, I	REGN7999	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change